Two teens, who cannot be named for legal reasons, appeared in court this morning
A judge has said the trial of two teenagers accused of murdering 16-year-old Rohan 'Fred' Shand in Northampton last week is "a high priority" after the two appeared at Northampton Crown Court this morning, March 27.
READ MORE: Irthlingborough thug 'boasted' about violent Northampton attack that killed man, 18, in front of his pregnant partner “I won’t, sadly, be able to give you a trial date today. A plea and trial preparation hearing date will be provided to the parties very shortly.”
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Northampton: Memorial service to be held for fatally stabbed teenRohan Shand, known to his family and friends as Fred, died in Northampton on Wednesday.
Lire la suite »
Rohan Shand: Boys charged with Northampton murder appear in courtRohan Shand, 16, who was known as Fred, died after being stabbed in Northampton last week.
Lire la suite »
Town's one-way traffic trial to be made permanent after positive feedbackA one-way system first adopted 18 months ago in a Powys town is set to stay for good, the county council has revealed.
Lire la suite »
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications - Molecular NeurodegenerationAs the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence and clinical symptoms, challenges regarding practicality and accessibility hinder their widespread availability and implementation. Consequently, many people with suspected cognitive impairment due to AD do not receive a biomarker-supported diagnosis. Blood biomarkers have the capacity to help expand access to AD diagnostics worldwide. One such promising biomarker is plasma phosphorylated tau (p-tau), which has demonstrated specificity to AD versus non-AD neurodegenerative diseases, and will be extremely important to inform on clinical diagnosis and eligibility for therapies that have recently been approved. This review provides an update on the diagnostic and prognostic performances of plasma p-tau181, p-tau217 and p-tau231, and their associations with in vivo and autopsy-verified diagnosis and pathological hallmarks. Additionally, we discuss potential applications and unanswered questions of plasma p-tau for therapeutic trials, given their recent addition to the biomarker toolbox for participant screening, recruitment and during-trial monitoring. Outstanding questions include assay standardization, threshold generation and biomarker verification in diverse cohorts reflective of the wider community attending memory clinics and included in clinical trials.
Lire la suite »
Why the Gwyneth Paltrow ski trial could get even more absurd this weekThe actress could barely contain her laughter when Terry Sanderson’s lawyer asked if her friend Taylor Swift was the inspiration for her suing for $1
Lire la suite »
A randomized trial of a blood thinner after severe COVID-19 to prevent clotting eventsIn a recent prospective study published in the Annals of Internal Medicine Journal, researchers in the United States (US) and Spain performed a randomized controlled trial (RCT) across 127 US hospitals between 2021 and 2022.
Lire la suite »